Disruption of the NMDA Receptor GluN2A Subunit Abolishes Inflammation-induced Depression
Overview
Psychology
Social Sciences
Affiliations
Recent reports have demonstrated that lipopolysaccharide (LPS)-induced depressive-like behaviour is mediated via NMDA receptor. In this study, we further investigated the role of GluN2 A subunit of NMDA receptor in synaptic processes in the prefrontal cortex (PFC) and hippocampus of GluN2 A knockout (KO) mice in LPS-induced depressive-like behavior. Our data suggest that LPS-treated mice, lacking GluN2 A subunit, did not exhibit depressive-like behaviour. This was accompanied by unaltered levels of IL-6 and significant changes in neuroplasticity markers and glutamate receptor subunits composition in PFC and hippocampus. In particular, an immune challenge in GluN2 A KO mice resulted in unchanged PSA-NCAM levels and proBDNF increase in both brain structures as well as in increase in BDNF levels in hippocampus. Furthermore, the absence of GluN2 A resulted in increased levels of all NCAM isoforms in PFC upon LPS which was followed with a decrease in GluN1 and GluN2B subunits. The levels of AMPA receptor subunits (GluA1, GluA3, and GluA4) in the hippocampus of GluN2 A mice were unaltered upon the treatment and abundantly present in the PFC of KO mice. These results indicate that the GluN2 A subunit is critical in neuroinflammation-related depression, that its absence abolishes LPS-induced depressive phenotype, sustains PSA-NCAM levels, increases proBDNF signalling in the PFC and hippocampus and potentiates synaptic stabilization through NCAM in the PFC upon an immune challenge.
Floris G, Zanda M, Dabrowski K, Daws S Transl Psychiatry. 2024; 14(1):500.
PMID: 39702361 PMC: 11659471. DOI: 10.1038/s41398-024-03203-4.
Immune and neural response to acute social stress in adolescent humans and rodents.
Gabbay V, Ely B, Vileisis J, Petrovic Z, Cicvaric A, Asnis G Transl Psychiatry. 2024; 14(1):306.
PMID: 39054336 PMC: 11272929. DOI: 10.1038/s41398-024-03008-5.
Ge C, Chen W, Zhang L, Ai Y, Zou Y, Peng Q Theranostics. 2023; 13(9):2946-2961.
PMID: 37284451 PMC: 10240833. DOI: 10.7150/thno.82889.
Siddiqui F, Gallagher D, Shuster-Hyman H, Lopez L, Gauthier-Fisher A, Librach C J Inflamm (Lond). 2023; 20(1):15.
PMID: 37127610 PMC: 10152638. DOI: 10.1186/s12950-023-00340-3.
He J, Zhou H, Wang F, Chen J Biol Psychiatry Glob Open Sci. 2023; 3(2):187-196.
PMID: 37124348 PMC: 10140449. DOI: 10.1016/j.bpsgos.2022.02.007.